Trial ID or NCT#

NCT02464228

Status

not recruiting iconNOT RECRUITING

Purpose

Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL). Tipifarnib will be administered orally until disease progression.

Official Title

An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Ranjana Advani
Ranjana Advani
Medical oncologist, Lymphoma specialist
Saul A. Rosenberg, MD, Professor of Lymphoma
Lauren Maeda
Lauren Maeda
Clinical Associate Professor, Medicine - Oncology Clinical Assistant Professor, Medicine - Hematology
Hans-Christoph Becker, MD, FSABI, FSCCT
Radiologist
Clinical Professor, Radiology
Neel K. Gupta
Neel K. Gupta
Medical oncologist
Clinical Assistant Professor, Medicine - Oncology Clinical Assistant Professor, Medicine - Hematology

Contact us to find out if this trial is right for you.

CONTACT

Luu Q. Pham
(650) 736-6432